AstraZeneca to buy Amolit Pharma for $1.05bn to boost rare disease portfolio
Drug maker AstraZeneca said on Thursday it will acquire rare endocrine disease company Amolyt Pharma for $1.05 billion in cash in a bid to boost its rare disease portfolio.
POPULAR POSTS
‘The Kardashians’ renewed by Hulu for 20 more episodes
July 26, 2024
Death toll from landslides in Ethiopia could rise to 500
July 26, 2024
The Canadian wildfire has made its way to Jasper
July 26, 2024
LIVE STREAM
